Skip to main content
. 2014 Apr 27;7:45. doi: 10.1186/1757-2215-7-45

Figure 3.

Figure 3

Characterization of ovarian cancer cells made resistant to CDDP and PTX. (A) Percent of cell growth [a-c] and sub-G1 DNA content [d-f] in IGROV-1 and IGROV-1 PTES cells. (B) Percent of cell growth [a-c] and sub-G1 DNA content [d-f] in SKOV-3 and SKOV-3 PTES cells. Percent growth was expressed in relation to the growth of vehicle treated controls considered as 100%. Percent specific sub-G1 was calculated by the following equation: specific sub-G1 = [100* (sub-G1 treatment – sub-G1 control) / (100 - control sub- G1)]. Data presented in panels [a-f] were collected after 96 h treatment. FRA; fold resistance acquired; CDP: combination dose proportion, where CDP 1 represents 20 μM CDDP + 100 nM PTX, CDP 0.25 represents 5 μM CDDP + 25 nM PTX, CDP 0.5 represents 10 μM CDDP + 50 nM PTX, whereas CDP 2 represents 40 μM CDDP + 200 nM PTX.